Schizophrenia 9

Summary

Schizophrenia 9 (MONDO:0011498) is a disease. A subtype of schizophrenia, susceptibility to — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• ClinVar variants: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	schizophrenia 9
Mondo ID	MONDO:0011498
OMIM	604906
DOID	DOID:0070085
UMLS	C1858050
MedGen	346728
Is cancer (heuristic)	no

Also known as: schizophrenia 9 · schizophrenia 9, susceptibility to · schizophrenia type 9 · SCZD9

Data availability: 1 ClinVar variant.

Disease family

This is a subtype of schizophrenia, susceptibility to. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease susceptibility › inherited disease susceptibility › schizophrenia, susceptibility to › schizophrenia 9

Related subtypes (5): schizophrenia 4, schizophrenia 6, schizophrenia 14, schizophrenia 13, schizophrenia 18

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

1 retrieved; paginated sample, class counts are floors:

1 risk factor

ClinVar	Variant (HGVS)	Gene	Classification	Review
5172	NM_018662.3(DISC1):c.[67+5859A>T;791G>A]		risk factor	no assertion criteria provided

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.